Andy Chen
Stock Analyst at Wolfe Research
(2.18)
# 2,724
Out of 4,868 analysts
38
Total ratings
42.31%
Success rate
-0.83%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Andy Chen
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BBIO BridgeBio Pharma | Initiates: Outperform | $49 | $40.00 | +22.50% | 1 | Jun 17, 2025 | |
| SRPT Sarepta Therapeutics | Initiates: Peer Perform | n/a | $20.77 | - | 1 | Jun 17, 2025 | |
| RNA Avidity Biosciences | Initiates: Outperform | $55 | $29.32 | +87.59% | 1 | Jun 17, 2025 | |
| BPMC Blueprint Medicines | Downgrades: Peer Perform | n/a | $128.12 | - | 1 | Jun 3, 2025 | |
| MLTX MoonLake Immunotherapeutics | Upgrades: Outperform | $61 | $43.50 | +40.23% | 3 | May 19, 2025 | |
| NTLA Intellia Therapeutics | Upgrades: Outperform | $21 | $9.60 | +118.75% | 2 | Apr 21, 2025 | |
| ANAB AnaptysBio | Initiates: Outperform | n/a | $23.39 | - | 1 | Feb 4, 2025 | |
| CRNX Crinetics Pharmaceuticals | Initiates: Peer Perform | n/a | $30.50 | - | 1 | Feb 4, 2025 | |
| ETNB 89bio | Initiates: Outperform | n/a | $10.00 | - | 1 | Feb 4, 2025 | |
| ORKA Oruka Therapeutics | Initiates: Outperform | $20 | $11.98 | +66.94% | 1 | Feb 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $49 | $20.92 | +134.23% | 1 | Feb 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $19 | $9.39 | +102.34% | 1 | Feb 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Peer Perform | n/a | $15.86 | - | 2 | Jan 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $697 | $537.92 | +29.57% | 2 | Nov 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | n/a | $312.32 | - | 2 | Nov 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $68.27 | - | 1 | Oct 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Peer Perform | n/a | $20.82 | - | 3 | Sep 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $65 | $46.44 | +39.97% | 2 | Aug 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $54.90 | - | 1 | Jun 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $282.72 | - | 1 | Jun 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $15.00 | - | 1 | Jun 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Peer Perform | n/a | $7.42 | - | 3 | May 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | n/a | $37.01 | - | 1 | Apr 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Peer Perform | n/a | $44.43 | - | 1 | Feb 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $17 | $11.44 | +48.60% | 1 | Feb 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $448.40 | - | 1 | Feb 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $42 | $99.46 | -57.77% | 1 | Feb 15, 2024 |
BridgeBio Pharma
Jun 17, 2025
Initiates: Outperform
Price Target: $49
Current: $40.00
Upside: +22.50%
Sarepta Therapeutics
Jun 17, 2025
Initiates: Peer Perform
Price Target: n/a
Current: $20.77
Upside: -
Avidity Biosciences
Jun 17, 2025
Initiates: Outperform
Price Target: $55
Current: $29.32
Upside: +87.59%
Blueprint Medicines
Jun 3, 2025
Downgrades: Peer Perform
Price Target: n/a
Current: $128.12
Upside: -
MoonLake Immunotherapeutics
May 19, 2025
Upgrades: Outperform
Price Target: $61
Current: $43.50
Upside: +40.23%
Intellia Therapeutics
Apr 21, 2025
Upgrades: Outperform
Price Target: $21
Current: $9.60
Upside: +118.75%
AnaptysBio
Feb 4, 2025
Initiates: Outperform
Price Target: n/a
Current: $23.39
Upside: -
Crinetics Pharmaceuticals
Feb 4, 2025
Initiates: Peer Perform
Price Target: n/a
Current: $30.50
Upside: -
89bio
Feb 4, 2025
Initiates: Outperform
Price Target: n/a
Current: $10.00
Upside: -
Oruka Therapeutics
Feb 4, 2025
Initiates: Outperform
Price Target: $20
Current: $11.98
Upside: +66.94%
Feb 4, 2025
Initiates: Outperform
Price Target: $49
Current: $20.92
Upside: +134.23%
Feb 4, 2025
Initiates: Outperform
Price Target: $19
Current: $9.39
Upside: +102.34%
Jan 3, 2025
Downgrades: Peer Perform
Price Target: n/a
Current: $15.86
Upside: -
Nov 12, 2024
Upgrades: Outperform
Price Target: $697
Current: $537.92
Upside: +29.57%
Nov 12, 2024
Downgrades: Underperform
Price Target: n/a
Current: $312.32
Upside: -
Oct 1, 2024
Initiates: Outperform
Price Target: n/a
Current: $68.27
Upside: -
Sep 27, 2024
Downgrades: Peer Perform
Price Target: n/a
Current: $20.82
Upside: -
Aug 26, 2024
Upgrades: Outperform
Price Target: $65
Current: $46.44
Upside: +39.97%
Jun 11, 2024
Initiates: Outperform
Price Target: n/a
Current: $54.90
Upside: -
Jun 11, 2024
Initiates: Outperform
Price Target: n/a
Current: $282.72
Upside: -
Jun 11, 2024
Initiates: Outperform
Price Target: n/a
Current: $15.00
Upside: -
May 14, 2024
Downgrades: Peer Perform
Price Target: n/a
Current: $7.42
Upside: -
Apr 10, 2024
Upgrades: Outperform
Price Target: n/a
Current: $37.01
Upside: -
Feb 15, 2024
Initiates: Peer Perform
Price Target: n/a
Current: $44.43
Upside: -
Feb 15, 2024
Initiates: Outperform
Price Target: $17
Current: $11.44
Upside: +48.60%
Feb 15, 2024
Initiates: Outperform
Price Target: n/a
Current: $448.40
Upside: -
Feb 15, 2024
Initiates: Outperform
Price Target: $42
Current: $99.46
Upside: -57.77%